151 related articles for article (PubMed ID: 35870)
1. Antilymphocytic antibodies and marrow transplantation. VI. Graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow with absorbed antithymocyte globulin.
Kolb HJ; Rieder I; Rodt H; Netzel B; Grosse-Wilde H; Scholz S; Schäffer E; Kolb H; Thierfelder S
Transplantation; 1979 Apr; 27(4):242-5. PubMed ID: 35870
[No Abstract] [Full Text] [Related]
2. Bone marrow transplantation in DLA-haploidentical canine littermates: fractionated total body irradiation (FTBI) and in vitro treatment of the marrow graft with anti-T-cell globulin (ATCG).
Kolb HJ; Bodenberger U; Rodt HV; Rieder I; Netzel B; Grosse-Wilde H; Scholz S; Thierfelder S
Haematol Blood Transfus; 1980; 25():61-71. PubMed ID: 7021361
[No Abstract] [Full Text] [Related]
3. Graft versus host tolerance in dogs across one DLA-haplotype by depletion of CD6 positive cells.
Schumm M; Kolb HJ; Hahn J; Beisser K; Rieber P; Günther W; Büttner M; Wilmanns W; Thierfelder S
Prog Clin Biol Res; 1992; 377():419-25. PubMed ID: 1438440
[No Abstract] [Full Text] [Related]
4. Use of antithymocyte serum in clinical and experimental marrow transplantation.
Storb R; Weiden PL; Thomas ED
Postgrad Med J; 1976; 52(5 Suppl):96-103. PubMed ID: 11456
[TBL] [Abstract][Full Text] [Related]
5. Antilymphocytic antibodies and marrow transplantation. VI. Absence of immunosuppression in vivo after injection of monoclonal antibodies blocking graft-versus-host reactions and humoral antibody formation in vitro.
Thierfelder S; Hoffmann-Fezer G; Rodt H; Doxiadis I; Eulitz M; Kummer U
Transplantation; 1983 Mar; 35(3):249-54. PubMed ID: 6340277
[TBL] [Abstract][Full Text] [Related]
6. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow transplantation and (or) immunosuppression with antithymocyte globulin in the treatment of aplastic anemia].
Zwaan FE; Haak HL; van der Meer CW; Guiot HF; Hartgrink-Groeneveld CA; den Ottolander GJ; Willemze R; Eernisse JG; Brand A; van Rood JJ; Kunst MW; te Velde J; Noordwijk EM
Ned Tijdschr Geneeskd; 1978 Mar; 122(10):326-32. PubMed ID: 24811
[No Abstract] [Full Text] [Related]
8. Modulation of immune reactions by antilymphocyte serum.
Müller-Ruchholtz W; Wottge HU; Müller-Hermelink HK
Transplant Proc; 1978 Mar; 10(1):23-9. PubMed ID: 24907
[No Abstract] [Full Text] [Related]
9. Antilymphocytic antibodies and marrow transplantation. V. Suppression of secondary disease by host-versus-theta-graft reaction.
Thierfelder S; Rodt H
Transplantation; 1977 Jan; 23(1):87-92. PubMed ID: 319574
[TBL] [Abstract][Full Text] [Related]
10. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study.
Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH
J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174
[TBL] [Abstract][Full Text] [Related]
11. The double barrier in bone marrow transplantation.
van Bekkum DW
Semin Hematol; 1974 Jul; 11(3):325-40. PubMed ID: 4151846
[No Abstract] [Full Text] [Related]
12. Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants.
Vallera DA; Soderling CC; Kersey JH
J Immunol; 1982 Feb; 128(2):871-5. PubMed ID: 6172513
[TBL] [Abstract][Full Text] [Related]
13. Regulation and suppression of graft-versus-host reaction.
Nouza K; Pichlílová
Allerg Immunol (Leipz); 1973; 19(2-4):279-89. PubMed ID: 4156162
[No Abstract] [Full Text] [Related]
14. Bone marrow transplantation in inbred strains of mice. I. The failure of development of normal T cell function following allogeneic transplantation.
Trier L; Rubin B
Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Oct; 82B(5):724-32. PubMed ID: 4139875
[No Abstract] [Full Text] [Related]
15. Failure of antithymocyte serum postgrafting to overcome "resistance" to DLA-nonidentical canine marrow grafts.
Storb R; Raff RF; Appelbaum FR; Schuening F; Sandmaier B; Shulman H; Deeg HJ; Graham T
Transplantation; 1988 Jan; 45(1):236-9. PubMed ID: 3276053
[No Abstract] [Full Text] [Related]
16. Progress in the prevention of GVH: bone marrow grafts after ALG conditioning, with lymphocyte split chimerism, use of a lymphocyte "chalone T", and soluble histocompatibility antigens.
Mathé G; Kiger N; Florentin I; Garcia-Giralt E; Martyre MC; Halle-Pannenko O; Schwartzenberg L
Transplant Proc; 1973 Mar; 5(1):933-9. PubMed ID: 4144474
[No Abstract] [Full Text] [Related]
17. Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
Thierfelder S; Cobbold S; Kummer U; Waldmann H; Schuh R
Exp Hematol; 1985 Oct; 13(9):948-55. PubMed ID: 2864278
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunology and the pathogenesis of graft versus host reactions.
Elkins WL
Prog Allergy; 1971; 15():78-187. PubMed ID: 4151282
[No Abstract] [Full Text] [Related]
19. Bone marrow transplantation across the major histocompatibility barrier in specific-pathogen-free mice: effects of intact versus T cell-depleted bone marrow on the expression of anti-host reaction in the recipient spleens.
Muto M; Sado T; Aizawa S; Kamisaku H; Kubo E
J Immunol; 1981 Dec; 127(6):2421-5. PubMed ID: 6457876
[No Abstract] [Full Text] [Related]
20. Recipient-specific donor cytotoxic T lymphocytes enhance engraftment of unrelated, DLA non-identical canine marrow.
Schwarzinger I; Raff RF; Flowers M; Niederwieser D; Graham T; Shulman H; Appelbaum FR; Schuening F; Storb R
Bone Marrow Transplant; 1994 Mar; 13(3):303-9. PubMed ID: 8199572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
